LAMEA Oncology/Anti-cancer drugs Market - Opportunities and Forecasts, 2014 - 2021 Published on – 1 February, 2016 | Number of pages : 108 Single User Price: $2580
The research methodology used to estimate and forecast LAMEA Oncology/Anti-cancer drugs Market begins with capturing data on key vendor revenue through the secondary research.
Summary of the Report: The Oncology or anti - cancer drugs are the drugs that are often used for the treatment of the cancer patients. Some of the common cancers that are rampant currently are prostate cancer, ovarian cancer, testicular cancer, adenocarcinoma, pancreatic cancer, colon cancer etc. The LAMEA Oncology/Anti-cancer Drugs Market deals with the production, supply and distribution along with scope and demand in the LAMEA region during 2014-2021.
Click Here To Check Complete Report
Topics Covered in this report : Scope of the LAMEA Oncology/Anti-cancer Drugs Market: The LAMEA Oncology/Anti-cancer Drugs Market is expected to reach $17,072.2 million by 2021. The rising cases of cancer, increasing investment by the government for research and development, capital expenditure by drug companies to develop drugs are the major factors driving this market during 2014-2021. Anti - cancer drugs patent expiration of Herceptin (Patent Expiration: EU-2014; US2019), Erbitux (Patent Expiration: EU-2014; US-2016), Rituxan (Patent Expiration: EU2013; US-2018) and Avastin (Patent Expiration: EU-2018; US-2019) is expected to boost the production and supply growth of the LAMEA Oncology/Anti-cancer Drugs Market in LAMEA.
In the LAMEA Oncology/Anti-cancer Drugs Market, the biological therapy is expected to grow at a CAGR of 12.2% by 2021, whereas the blood cancer drugs are the largest segment to generate revenues during 2015. Brazil dominated this market with high investment and sales, closely followed by Argentina. LAMEA is poised to grow at a CAGR of 8.6% in this market during 2014-2021. Segmentation and Key Players of the LAMEA Oncology/Anti-cancer Drugs Market: The LAMEA Oncology/Anti-cancer Drugs Market is segmented into various categories by therapeutic modalities, by cancer type and by country as follows:
By therapeutic modalities: Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy and others By cancer type: Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Respiratory/Lung Cancer, Skin Cancer and other Cancers By country: Brazil, Argentina, Nigeria, South Africa, Iraq, Iran, Algeria, Saudi Arabia and Egypt
Download Sample Brochure
The key players in the LAMEA Oncology/Anti-cancer Drugs Market are as follows: • AstraZeneca Plc. • Roche Diagnostics • Sanofi • Novartis • GlaxoSmithKline PLC The LAMEA Oncology/Anti-cancer Drugs Market is a rapidly growing market due to increasing cases of various cancer types in the population of the LAMEA region. This market is expected to witness high growth owing to increasing R&D investment by medical corporations, growing cases of cancer such as liver cancer, thyroid cancer, stomach cancer, bone cancer and others, affordability of cancer drugs and many others in the LAMEA region during 2014-2021.
Inquiry Before Buying
LAMEA Oncology/Anti-cancer drugs Market - Opportunities and Forecasts, 2014 - 2021 A detailed qualitative analysis of the factors responsible for driving and restraining growth of the LAMEA Oncology/Anti-cancer drugs Market and future opportunities are provided in the report.
Contact: 1-302-261-5343 sales@marketintelreports.com www.marketintelreports.com
Click here to order a copy of LAMEA Oncology/Anti-cancer drugs Market 2014-2021 Research Report